Can Bausch + Lomb’s PreserVision AREDS3 shift the AMD supplement market beyond AREDS2 alone?
Bausch + Lomb’s PreserVision AREDS3 adds B vitamins to the AMD nutrition debate. Read what this could change for eye health and market strategy.
Samsung Bioepis takes over BYOOVIZ commercialization in Europe after Biogen exit
Samsung Bioepis has officially begun direct commercialization of BYOOVIZ, a biosimilar to Lucentis (ranibizumab), across Europe following the complete transfer of rights from Biogen. The move makes BYOOVIZ the fourth biosimilar now independently marketed by Samsung Bioepis in the region, joining EPYSQLI (eculizumab), OBODENCE (denosumab), and XBRYK (denosumab). The company also confirmed that a pre-filled […]